Search research articles
Contact Us
Filters
Showing results (161-170 of 180) with videos related to
Page
of 18
Sort By:
International Journal of Cancer
|
January 3, 1996
Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues
L Panico, A D'Antonio, G Salvatore, et al.
International Journal of Obesity (2005)
|
November 21, 2017
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling
C Carbone, G Piro, N Gaianigo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2022
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
R Iacovelli, C Ciccarese, M Brunelli, et al.
ESMO Open
|
August 30, 2025
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib
E Vita, A Scala, A Vitale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 29, 2019
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
P Hammel, H L Kindler, M Reni, et al.
ESMO Open
|
July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
V Daprà, A Gandini, F Schietroma, et al.
ESMO Gastrointestinal Oncology
|
March 27, 2026
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study
G Trovato, M Carullo, A Nicastro, et al.
ESMO Open
|
November 8, 2025
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis
G Trovato, D Rossini, A Guidolin, et al.
Cell Death & Disease
|
December 5, 2024
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance
A Esposito, A Agostini, G Quero, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 180) with videos related to
Sort By:
Page
of 18
International Journal of Cancer
|
January 3, 1996
Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues
L Panico, A D'Antonio, G Salvatore, et al.
International Journal of Obesity (2005)
|
November 21, 2017
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling
C Carbone, G Piro, N Gaianigo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2022
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
R Iacovelli, C Ciccarese, M Brunelli, et al.
ESMO Open
|
August 30, 2025
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib
E Vita, A Scala, A Vitale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 29, 2019
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
P Hammel, H L Kindler, M Reni, et al.
ESMO Open
|
July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
V Daprà, A Gandini, F Schietroma, et al.
ESMO Gastrointestinal Oncology
|
March 27, 2026
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study
G Trovato, M Carullo, A Nicastro, et al.
ESMO Open
|
November 8, 2025
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis
G Trovato, D Rossini, A Guidolin, et al.
Cell Death & Disease
|
December 5, 2024
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance
A Esposito, A Agostini, G Quero, et al.
Page
of 18